Page last updated: 2024-09-03

vadimezan and sb 203580

vadimezan has been researched along with sb 203580 in 2 studies

Compound Research Comparison

Studies (vadimezan)	Trials (vadimezan)	Recent Studies (post-2010) (vadimezan)	Studies (sb 203580)	Trials (sb 203580)	Recent Studies (post-2010) (sb 203580)
272	16	101	3,489	4	1,137

Protein Interaction Comparison

Protein	Taxonomy	sb 203580 (IC50)
Citron Rho-interacting kinase	Homo sapiens (human)	1
Cyclin-G-associated kinase	Homo sapiens (human)	0.4133
Mitogen-activated protein kinase 13	Homo sapiens (human)	0.2329
Mitogen-activated protein kinase 2	Pneumocystis carinii	0.105
Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)	1.0359
RAF proto-oncogene serine/threonine-protein kinase	Homo sapiens (human)	0.7575
Cytochrome P450 1A2	Homo sapiens (human)	2
Tyrosine-protein kinase Lck	Homo sapiens (human)	3.45
Neutrophil elastase	Homo sapiens (human)	0.025
Cytochrome P450 3A4	Homo sapiens (human)	0.062
Cytochrome P450 2D6	Homo sapiens (human)	2
Tyrosinase	Mus musculus (house mouse)	0.034
Cholesteryl ester transfer protein	Homo sapiens (human)	0.04
Cytochrome P450 2C9	Homo sapiens (human)	1
Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)	5
Serine/threonine-protein kinase B-raf	Homo sapiens (human)	1
Amine oxidase [flavin-containing] B	Rattus norvegicus (Norway rat)	0.36
Prostaglandin G/H synthase 1	Homo sapiens (human)	2
Thromboxane-A synthase	Homo sapiens (human)	0.494
Adenosine receptor A2a	Homo sapiens (human)	6.068
Ephrin type-B receptor 2	Homo sapiens (human)	7.8
Adenosine receptor A1	Homo sapiens (human)	2.95
Sodium-dependent serotonin transporter	Rattus norvegicus (Norway rat)	0.01
Delta-type opioid receptor	Mus musculus (house mouse)	0.02
Cytochrome P450 2C19	Homo sapiens (human)	0.8
TGF-beta receptor type-1	Homo sapiens (human)	6
Mitogen-activated protein kinase 9	Homo sapiens (human)	0.9517
Mitogen-activated protein kinase 14	Mus musculus (house mouse)	0.056
Casein kinase I isoform delta	Homo sapiens (human)	0.4147
Casein kinase I isoform epsilon	Homo sapiens (human)	1
Mitogen-activated protein kinase 12	Homo sapiens (human)	0.2329
Mitogen-activated protein kinase 10	Homo sapiens (human)	0.6933
Mitogen-activated protein kinase 1	Rattus norvegicus (Norway rat)	0.048
Myotonin-protein kinase	Homo sapiens (human)	1
Mitogen-activated protein kinase 11	Homo sapiens (human)	0.2646
Mitogen-activated protein kinase 14	Homo sapiens (human)	0.39
P2X purinoceptor 7	Homo sapiens (human)	5
Serine/threonine-protein kinase 36	Homo sapiens (human)	1
Serine/threonine-protein kinase NLK	Homo sapiens (human)	1
TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)	1

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baguley, BC; Kelland, LR; Marshall, ES; Zhao, L	1
Albelda, SM; Cheng, G; Ching, LM; Fridlender, ZG; Sun, J; Wang, LC	1

Other Studies

2 other study(ies) available for vadimezan and sb 203580

Article	Year
Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Investigational new drugs, 2007, Volume: 25, Issue:3 Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Cell Line, Tumor; Cell Proliferation; Cell Shape; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Laminin; MAP Kinase Signaling System; Melanoma; Mice; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proteoglycans; Pyridines; RNA, Messenger; Xanthones; Xenograft Model Antitumor Assays	2007
Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan). The Journal of biological chemistry, 2010, Apr-02, Volume: 285, Issue:14 Topics: Antineoplastic Agents; Cells, Cultured; Chemokine CXCL10; Enzyme Inhibitors; Humans; Imidazoles; Immunoblotting; Kidney; Luciferases; Mesothelioma; NF-kappa B; Nod1 Signaling Adaptor Protein; Nod2 Signaling Adaptor Protein; Nucleotides; Pyridines; Receptor-Interacting Protein Serine-Threonine Kinase 2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Xanthones	2010

Article

Year

Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

Investigational new drugs, 2007, Volume: 25, Issue:3

Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Cell Line, Tumor; Cell Proliferation; Cell Shape; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Laminin; MAP Kinase Signaling System; Melanoma; Mice; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proteoglycans; Pyridines; RNA, Messenger; Xanthones; Xenograft Model Antitumor Assays

2007

Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan).

The Journal of biological chemistry, 2010, Apr-02, Volume: 285, Issue:14

Topics: Antineoplastic Agents; Cells, Cultured; Chemokine CXCL10; Enzyme Inhibitors; Humans; Imidazoles; Immunoblotting; Kidney; Luciferases; Mesothelioma; NF-kappa B; Nod1 Signaling Adaptor Protein; Nod2 Signaling Adaptor Protein; Nucleotides; Pyridines; Receptor-Interacting Protein Serine-Threonine Kinase 2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Xanthones

2010